TruScreen widens annual loss as delayed certification hits sales

TruScreen widens annual loss as delayed certification hits sales
Sophie Boot
By Sophie Boot June 14 (BusinessDesk) - TruScreen, the NZAX-listed cervical cancer test developer, widened its annual loss as revenue dropped 21 percent because of delays in getting a new device certified. The Auckland-based company reported a net loss of $1.3 million in the year ended March 31, from $692,077 a year earlier. Revenue fell to $1.84 million from $2.22 million a year earlier. Within that, revenue from sales slumped to $472,104, from $1.57 million in the 2015 year, while 'other income' more than doubled to $1.37 million. Mo...